- Home
- MCRB vs ZURA Comparison
MCRB vs ZURA Comparison
Compare MCRB & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCRB
- ZURA
- Stock Information
- Founded
- MCRB 2010
- ZURA 2022
- Country
- MCRB United States
- ZURA United States
- Employees
- MCRB N/A
- ZURA N/A
- Industry
- MCRB Biotechnology: Pharmaceutical Preparations
- ZURA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MCRB Health Care
- ZURA Health Care
- Exchange
- MCRB Nasdaq
- ZURA Nasdaq
- Market Cap
- MCRB 72.0M
- ZURA 76.6M
- IPO Year
- MCRB 2015
- ZURA N/A
- Fundamental
- Price
- MCRB $7.05
- ZURA $1.01
- Analyst Decision
- MCRB Hold
- ZURA Buy
- Analyst Count
- MCRB 5
- ZURA 7
- Target Price
- MCRB $73.67
- ZURA $14.33
- AVG Volume (30 Days)
- MCRB 93.5K
- ZURA 520.6K
- Earning Date
- MCRB 05-07-2025
- ZURA 05-08-2025
- Dividend Yield
- MCRB N/A
- ZURA N/A
- EPS Growth
- MCRB N/A
- ZURA N/A
- EPS
- MCRB 8.98
- ZURA N/A
- Revenue
- MCRB N/A
- ZURA N/A
- Revenue This Year
- MCRB N/A
- ZURA N/A
- Revenue Next Year
- MCRB N/A
- ZURA N/A
- P/E Ratio
- MCRB $0.84
- ZURA N/A
- Revenue Growth
- MCRB N/A
- ZURA N/A
- 52 Week Low
- MCRB $6.53
- ZURA $0.97
- 52 Week High
- MCRB $30.60
- ZURA $5.56
- Technical
- Relative Strength Index (RSI)
- MCRB 38.95
- ZURA 35.69
- Support Level
- MCRB $7.32
- ZURA $0.99
- Resistance Level
- MCRB $7.86
- ZURA $1.06
- Average True Range (ATR)
- MCRB 0.63
- ZURA 0.08
- MACD
- MCRB 0.10
- ZURA -0.01
- Stochastic Oscillator
- MCRB 28.89
- ZURA 7.17
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.